+ All Categories
Home > Healthcare > ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO...

ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO...

Date post: 08-Jul-2015
Category:
Upload: national-organization-of-peer-educators-nope-kenya
View: 96 times
Download: 0 times
Share this document with a friend
Popular Tags:
23
ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS Eva Muluve, John Lizcano, Helga Musyoki, Martin Sirengo, Charles M. Cleland, Ann Kurth, Peter Cherutich 6 th Conference on Peer Education, Sexuality, HIV/AIDS June 18, 2014
Transcript
Page 1: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF

CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Eva Muluve, John Lizcano, Helga Musyoki, Martin Sirengo, Charles M. Cleland, Ann Kurth, Peter Cherutich

6th Conference on Peer Education, Sexuality, HIV/AIDSJune 18, 2014

Page 2: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Presentation outline

• Background of the Test and Link to Care for Injecting Drug Users Study (TLC- IDU Study)

• Study Setting

• Study design, aims and anticipated outcomes

• Point of Care CD4 testing

• Results

• Conclusion

Page 3: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Background

• HIV infections in sub-Saharan Africa increasingly occur among people who inject drugs (PWID)

• Needle & syringe programs (NSP) and PWID-specific ART support have been nearly non-existent

• Kenya is among the first to implement gov’t-run NSP at a country-wide level starting in 2013– We are using Responding-Driven Sampling (RDS)

to seek out PWID, deliver rapid HIV testing, point-of-care CD4, and peer-supported linkage to ART

– Will evaluate community viral load impact

Page 4: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Study Sites: Nairobi & Coastal Region

• Seek– Respondent-Driven Sampling (RDS) to

find PWID

• Test• Offer rapid HIV test at NSP service sites

(N=10)

• Treat– Offer point of care (POC) CD4 assay if

HIV+

• Retain– If HIV+ and CD4+ cell count <350/mm3

provide peer case manager (PCM) for linkage to care • Conditional cash transfer to participant &

PCM

Page 5: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Study Sites

Nairobi Region– Nairobi 1: NOSET – Ngara– Nairobi 2: NOSET – Racecource/Kawangware– Nairobi 3: MDM – Kangemi– Nairobi 4: SAPTA – Pangani

Coastal Region– Coast 1: Bomu – Likoni– Coast 2: Omari Project – Malindi– Coast 3: MEWA – Kilifi– Coast 4: Reachout – Oldtown Mombasa– Coast 5: Bomu Hospital – Changamwe– Coast 6: Teens Watch – Ukunda

Page 6: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Study Aims

Aim 1: Launch and evaluate TLC-IDU using a stepped wedge cluster randomized design

Aim 2: Conduct mathematical modeling to estimate community viral load in PWID injecting and sexual

networks and potential population-level impact

Aim 3: Assess incremental cost-effectiveness ratio of TLC-IDU, compared with standard care

Page 7: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Study Design • Ten sites, respondent-driven sampling, stepped wedge,

repeated surveys, HIV testing, viral load

Data Collection Periods

(6 Months Each)

1 2 3 4 5 6

5

4

3

2

1

Five Pairs of Sites

Randomized

to Start at Different

Times

Intervention

Control

done nowdone

Page 8: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Study Flow

10 Study Sites

PWID informed of study via staff, RDS, or service site personnel

Informed Consent

Behavioral Survey on Computer Tablets

Rapid HIV Testing

HIV- HIV+

Point of Care CD4 Test

CD4 <350CD4 ≥ 350

Peer Case Management

Viral Load testing (n=1,800 total)

GoK standard of care, refer for services including addiction treatment as needed

Inclusion Criteria:

≥ 18 years Live in Nairobi or Coast Ever injected any non-

prescribed drugs Any non-prescribed drugs

last 12 months

Page 9: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Biometrics & Data Management

Eliminates double enrollment in time wave

Tracks mobility, repeat services over time, incidence

Page 10: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Key Outcomes

• Successful linkage to care– # days between first test positive and first visit with HIV

provider

• Time to ART initiation – # days between first test positive and ART initiation

• ‘Community Viral Load’– Specimens at each site/waves over time from all PWID

who tests HIV+, to document changes in infectivity (median viral load)

– Using Dried Blood Spot (DBS) for VLs• Start collecting specimens for phylogenetic analysis

Page 11: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Point of Care CD4 Testing

• CD4 test is conducted for all HIV positive participants at intervention sites

• CD4 results are ready in maximum 20 minutes

• If CD4 <350mm/µl participant linked to peer case manager

Page 12: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Referral documents

Page 13: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Study Periods

• Study Period One

–May 25, 2012 – December 1, 2012

• Study Period Two

–April 22, 2013 – November 29, 2013

• Study Period Three

–January 31, 2014 - Ongoing

Page 14: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Recruitment and Demographics

Period One Period Two Period Three*

Screened 1947 1739 1048

Enrolled 1785 1489 984

% Male 86.8 87.9 91.0

% Married/Living as Married 14.2 14.8 14.9

% Nairobi 37.1 41.4 41.3

% Coast 62.9 58.6 58.7

% Mobile 20.1 25.3 22.4

% Participated Before -- 34.5 61.1

* Survey Period Three is in progress.

Page 15: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

HIV Testing Results

Page 16: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Unadjusted HIV Prevalence

Page 17: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

CD4

Page 18: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Viral Load among Participantswith HIV Infection

Page 19: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Undetectable Viral Load

Page 20: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Clinically Eligible ParticipantsRetained in Care

N = 2

N = 30

N = 6

N = 2

N = 2

Initiated ART, N = 40

Number of Participant Eligible for ART (N= 42)

Declined Services

Retained in care

Stopped ART

Died

In jail

All participants were linked to ART within 24 hours after testing. Initiation of ARVs took a maximum of 2 weeks.

Page 21: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Conclusion • Combination of RDS and rapid testing effective

strategy for finding PWID with HIV infection, including those not previously diagnosed

• Use of CD4 POC an effective strategy of determining eligibility to initiate PWIDs to ART

• Linkage to care by PCMs very effective for ART initiation

• Relationships built among the PCM, HIV-positive PWID, and HIV clinic staff have made linking to care significantly easier and have reduced discrimination towards PWID

Page 22: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Team Members

• NASCOP/MOH KENYA– Peter Cherutich (PI)

– Study team members

– Helgar Musyoki

– Martin Sirengo

• Expert Advisors, CAB– Claris Obiero, Elizabeth Ngugi,

Fred Owiti

– Don Des Jarlais, SteffanieStrathdee

NYUAnn Kurth (PI)Chuck ClelandScott BraithwaiteJohn Lizcano

Population CouncilJerry Okal, Scott Geibel

NSP Implementers (NGOs)

Thanks to NIH – NIDA1R01 DA032080

Redonna ChandlerShoshana KahanaDionne Jones

Page 23: ENHANCING HIV CARE AND TREATMENT THROUGH POINT OF CARE CD4 TESTING AND PEER SUPPORT FOR PEOPLE WHO INJECT DRUGS

Implementers, Staff, PCMs & Participants All photos have consent


Recommended